Overcoming Obstacles to MASH Diagnosis and Management

Target Audience

This activity is designed to educate gastroenterology and hepatology specialist physicians (MDs), nurse practitioners (NPs) and physician associates (PAs).

Program Overview

The approval of the first-ever pharmacotherapy specifically for metabolic dysfunction-associated steatohepatitis (MASH), resmetirom, has drastically altered clinical management. The rise of noninvasive tools (NITs) for diagnosis and fibrosis staging has necessitated changes to clinical practice and awareness of cutoff points for NITs to identify patients eligible for resmetirom. Because MASH is accompanied by cardiometabolic comorbidities, such as diabetes and obesity, clinicians should be familiar with glucagon-like peptide-1 (GLP-1) targeting therapies, which may be useful in managing these closely linked conditions. It is critical that clinicians be up to date on diagnostic strategies, nonpharmacologic and pharmacologic treatment strategies, and required disease monitoring. Dr. Naim Alkhouri describe recent advances in MASH diagnosis and management through an interactive platform, designed to help learners overcome common obstacles or challenges in clinical practice.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Incorporate noninvasive tools into practice that optimize diagnosis, staging, and monitoring of MASH
2. Review patient selection and monitoring criteria for FDA-approved MASH therapy according to expert recommendations
3. Create comprehensive management plans that address MASH and its cardiometabolic comorbidities

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Continuing Medical Education

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Reciprocity Statement

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

ABIM Credit Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Integritas' Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Integritas Communications permission to use this information/data to report your participation to these Boards via the Program and Activity Reporting System (PARS).

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live meeting and complete the posttest and program evaluation.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Naim Alkhouri, MD, FAASLD, DABOM

• Consulting Fees (e.g., advisory boards): 89bio, AbbVie, Akero, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, and Regeneron
• Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents  (e.g., speakers’ bureaus): AbbVie, AstraZeneca, Echosens, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, and Perspectum
• Contracted Research: 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Poxel, Regeneron, Viking Therapeutics, and Zydus

The Integritas Communications planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.